Início › Síndromes Mielodisplásicas › Ohio › Columbus
Ensaios clínicos de Síndromes Mielodisplásicas em Columbus, OH
14 estudos para Síndromes Mielodisplásicas estão buscando participantes em locais em Columbus e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
RecrutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecrutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecrutandoFase 1/2
- The Ohio State University, Columbus
Collection of Tissue Samples for Cancer Research
RecrutandoEstudo observacional
- Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
RecrutandoFase 1
- Ohio State University, The James Comprehensive Cancer, Columbus
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RecrutandoFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecrutandoFase 1/2
- Nationwide Children's Hospital, Columbus
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
RecrutandoFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecrutandoFase 2/3
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
RecrutandoFase 1
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecrutandoFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RecrutandoFase 1
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
HPC Offered for PRESERVE Expansion
RecrutandoEstudo observacional
- The Ohio State University Medical Center, Columbus
Ensaios de Síndromes Mielodisplásicas em outras cidades
- Houston, TX43 estudos
- Baldwin Park, CA26 estudos
- New York City, NY21 estudos
- Seattle, WA21 estudos
- Washington, DC20 estudos
- Boston, MA19 estudos
- Tampa, FL19 estudos
- Miami, FL17 estudos
- Durham, NC14 estudos
- Chicago, IL13 estudos
- Atlanta, GA13 estudos
- St. Louis, MO13 estudos
Outros estudos em Columbus
- Câncer de Pulmão de Não Pequenas Células56 estudos
- Câncer de Mama39 estudos
- Câncer de Ovário39 estudos
- Câncer (todos os tipos)38 estudos
- Câncer de Pulmão37 estudos
- Leucemia Mieloide Aguda35 estudos
- Leucemia Linfocítica Crônica28 estudos
- Câncer Metastático27 estudos
- Câncer Endometrial25 estudos
- Câncer Colorretal24 estudos
- Câncer de Próstata24 estudos
- Mieloma Múltiplo24 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.